Elan and Transition rejig Phase II Alzheimer's trials on safety data
This article was originally published in Scrip
Executive Summary
Elan and Transition Therapeutics have stopped using the two highest doses of their Alzheimer's disease drug candidate ELND005 in two Phase II trials due to safety concerns.